<div id="readability-page-1"><p>Bartlett &amp; CO. Wealth Management LLC lessened its holdings in shares of  Johnson &amp; Johnson (NYSE:JNJ - Free Report) by 5.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor  owned 254,517 shares of the company's stock after selling 13,578 shares during the period. Bartlett &amp; CO. Wealth Management LLC's holdings in Johnson &amp; Johnson were worth $47,192,000 at the end of the most recent quarter.</p><div><p><span></span><span>Get <strong>Johnson &amp; Johnson</strong> alerts:</span></p></div><ul><li>Rate Cuts Make These 3 Income ETFs More Attractive Than Ever</li></ul><p>A number of other large investors have also bought and sold shares of JNJ. Vanguard Group Inc. increased its position in shares of  Johnson &amp; Johnson by 1.3% during the second quarter. Vanguard Group Inc. now owns 237,047,859 shares of the company's stock worth $36,209,060,000 after acquiring an additional 3,085,180 shares in the last quarter.  Geode Capital Management LLC boosted its stake in  Johnson &amp; Johnson by 2.1% in the 2nd quarter. Geode Capital Management LLC now owns 60,609,476 shares of the company's stock worth $9,227,988,000 after purchasing an additional 1,225,676 shares during the period.  Norges Bank bought a new position in  Johnson &amp; Johnson during the 2nd quarter worth about $4,877,174,000.  Bank of New York Mellon Corp raised its stake in shares of  Johnson &amp; Johnson by 2.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 23,802,503 shares of the company's stock valued at $3,635,832,000 after purchasing an additional 620,039 shares during the period.  Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of  Johnson &amp; Johnson by 0.3% in the second quarter. Charles Schwab Investment Management Inc. now owns 18,951,337 shares of the company's stock valued at $2,894,979,000 after purchasing an additional 52,074 shares in the last quarter. 69.55% of the stock is owned by institutional investors. </p><h2>Johnson &amp; Johnson Price Performance</h2><p>Shares of JNJ opened at $206.49 on Monday. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. The company's fifty day simple moving average is $198.10 and its 200 day simple moving average is $179.38. Johnson &amp; Johnson has a 1-year low of $140.68 and a 1-year high of $215.18. The company has a market cap of $497.49 billion, a price-to-earnings ratio of 19.93, a PEG ratio of 2.24 and a beta of 0.36. </p><ul><li>Pfizer Adds to Its Big Bet on Weight Loss Drugs</li></ul><p>Johnson &amp; Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The company had revenue of $24.02 billion during the quarter. Johnson &amp; Johnson had a net margin of 27.26% and a return on equity of 32.73%.  On average, research analysts forecast that  Johnson &amp; Johnson will post 10.58 earnings per share for the current fiscal year. </p><h2>Johnson &amp; Johnson Announces Dividend</h2><p>The firm also recently declared a quarterly dividend, which was paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th were given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date of this dividend was Tuesday, November 25th. Johnson &amp; Johnson's payout ratio is 50.19%. </p><h2>Johnson &amp; Johnson News Roundup</h2><ul><li>5 Healthcare Names to Watch as Sector Rotation Is in Full Swing</li></ul><p>Here are the key news stories impacting Johnson &amp; Johnson this week:</p><ul>   <li><span>Positive Sentiment: </span>FDA approves a subcutaneous version of Rybrevant (amivantamab) that reduces administration time from hours to minutes for EGFR‑mutated NSCLC — this materially improves patient convenience, may raise uptake vs. IV therapy and supports long‑term revenue potential for JNJ’s lung‑cancer franchise. <i></i><span>J&amp;J Wins FDA Nod for Subcutaneous Version of NSCLC Drug Rybrevant</span></li>    <li><span>Positive Sentiment: </span>FDA clears RYBREVANT FASPRO (amivantamab + hyaluronidase) as the first subcutaneous therapy across Rybrevant indications, enabling much shorter, simpler first‑line regimens when combined with LAZCLUZE — a regulatory win that supports commercial uptake and margins. <i></i><span>U.S. FDA Approval of RYBREVANT FASPRO</span></li>    <li><span>Positive Sentiment: </span>JNJ’s MedTech unit won FDA clearance for the TRUFILL n‑BCA liquid embolic system to treat symptomatic chronic subdural hematoma (cSDH), expanding neurovascular indications and supporting device revenue growth. <i></i><span>Johnson &amp; Johnson Receives FDA Approval for TRUFILL n‑BCA</span></li>    <li><span>Positive Sentiment: </span>Media and investor sentiment is bullish: Jim Cramer highlighted JNJ’s oncology momentum and broader rotation into healthcare/defensive names, which can drive retail interest and support multiple expansion. <i></i><span>Jim Cramer Couldn’t Stop Gushing About Johnson &amp; Johnson (JNJ)’s Cancer Drugs</span></li>    <li><span>Neutral Sentiment: </span>Analyst/valuation commentary argues JNJ’s premium multiple is supported by accelerating growth and portfolio mix; useful context for longer‑term positioning but less likely to move near‑term price. <i></i><span>Johnson and Johnson: Valuation Premium Justified By Accelerating Growth</span></li>    <li><span>Neutral Sentiment: </span>Macro note: rate cuts and dividend‑friendly ETF flows (e.g., mentions in MarketBeat pieces) can support demand for high‑quality dividend payers like JNJ, but impact is gradual. <i></i><span>Rate Cuts Make These 3 Income ETFs More Attractive Than Ever</span></li>    <li><span>Negative Sentiment: </span>Near‑term pullback likely driven by profit‑taking after a large YTD move (shares are up significantly year‑to‑date); heavy volume suggests short‑term selling pressure despite positive catalysts. </li> </ul><h2>Analyst Ratings Changes</h2><p>A number of research firms recently issued reports on JNJ. Morgan Stanley increased their price objective on Johnson &amp; Johnson from $190.00 to $197.00 and gave the stock an &#34;equal weight&#34; rating in a report on Friday, December 12th. Wall Street Zen raised shares of Johnson &amp; Johnson from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research note on Saturday, September 13th. Royal Bank Of Canada  set a $240.00 price objective on shares of Johnson &amp; Johnson in a research report on Wednesday. UBS Group increased their target price on shares of Johnson &amp; Johnson from $190.00 to $214.00 and gave the stock a &#34;buy&#34; rating in a report on Tuesday, October 14th. Finally, BMO Capital Markets  reiterated an &#34;outperform&#34; rating on shares of Johnson &amp; Johnson in a research note on Thursday, December 11th. Four equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned  a Buy rating and nine have issued  a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $210.25.</p><p><b>Check Out Our Latest Stock Report on Johnson &amp; Johnson</b></p><h2>About Johnson &amp; Johnson</h2> (Free Report)<p>Johnson &amp; Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.  </p><p>The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Johnson &amp; Johnson</li><li>I Shouldn't Be Sending You This</li><li>REVEALED: America just unlocked a $500 trillion asset</li><li>Wall Street Stock picker Names #1 Stock of 2026</li><li>They Laughed at $30. They Won’t Laugh at $70.</li><li>How Long Will $1M Last in Retirement?</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Johnson &amp; Johnson Right Now?</h2><p>Before you consider Johnson &amp; Johnson, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson &amp; Johnson wasn't on the list.</p><p>While Johnson &amp; Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Bartlett & CO. Wealth Management LLC reduced its holdings in Johnson & Johnson by 5.1% in the 3rd quarter, now owning 254,517 shares worth $47.19 million. Other large investors like Vanguard, Geode Capital, and Norges Bank also adjusted their positions in JNJ. Johnson & Johnson's stock performance and recent FDA approvals for its products are highlighted, with positive sentiment from media and investors.</p>

Bartlett & CO. Wealth Management LLC Has $47.19 Million Stake in Johnson & Johnson $JNJ